Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681
Cancers, ISSN: 2072-6694, Vol: 14, Issue: 2
2022
- 3Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures3
- Readers3
Correction Description
The authors wish to make the following corrections to their paper [1]: 1. There was an error in the original publication. Page 3. “Monoallelic TP53 aberrations exert a more detrimental prognostic impact, compared to biallelic alterations.” This is incorrect. It should read: “Monoallelic TP53 alterations exert a less detrimental prognostic impact, compared to biallelic alterations.” 2. There was an error in the original publication. Page 13. “In fact, among our recently reported cohort of 20 spontaneously regressing CLL cases, three harbored TP53 mutations [2].” Reference [2] was erroneously cited. The correct reference here should be reference [1]. This sentence should read: “In fact, among our recently reported cohort of 20 spontaneously regressing CLL cases, three harbored TP53 mutations [1].” 3. There was an error in the original publication. Page 14. “in combination with existing immunomodulatory agents such as the PD-1/PD-L1 inhibitors lenalidomide and ibrutinib” This sentence should read in “in combination with existing immunomodulatory agents such as PD-1/PD-L1 inhibitors, lenalidomide and ibrutinib.” 4. In the original publication, there was a mistake in Table 1: “Döhner” was misspelt as “Doner”. The corrected Table 1 appears below. (Table Presented).
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know